All In Biotech

Free tool

FAERS Monitor: Abreva

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020941 or its brand name (Abreva, Docosanol). Reports on generic versions are filed under their own applications.

Reports

14,600

Serious

280

2% of reports

Hospitalization

133

Death reported

9

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective7,071
  • oral herpes2,458
  • condition aggravated1,967
  • drug administration error1,779
  • incorrect drug administration duration803
  • herpes simplex706
  • incorrect product administration duration642
  • lip swelling560
  • wrong technique in product usage process552
  • product quality issue539
  • inappropriate schedule of drug administration493
  • application site pain448
  • inappropriate schedule of product administration404
  • product complaint374
  • hypersensitivity319

Reports by year received

View as table
YearReports
20045
20051,157
20061,355
20071,648
20085
200914
20109
201117
201213
20132,116
2014216
20151,337
2016974
20171,006
20181,074
2019855
2020479
2021453
2022333
2023852
2024344
2025219
2026119

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,559 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
oral herpesSignal2,458207.4199.5441,588
herpes simplexSignal706175.4162.5109,026
drug administration errorSignal1,77988.684.7145,253
incorrect product administration durationSignal64244.040.726,142
incorrect drug administration durationSignal80342.339.531,462
application site painSignal44829.927.312,238
lip swellingSignal56024.622.712,475
product complaintSignal37421.619.57,216
inappropriate schedule of drug administrationSignal49310.09.23,993
condition aggravatedSignal1,9679.49.014,826
drug ineffectiveSignal7,0717.87.644,219
product quality issueSignal5395.75.32,108
wrong technique in product usage processSignal5523.93.61,212
inappropriate schedule of product administrationSignal4043.22.9625
hypersensitivitySignal3192.52.2282

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.